You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. NET- Selective Ligands for the Treatment of Depression

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increased global health burden for serious psychiatric disorders, particularly depression. Indeed, by 2020 it is expected that depression may be the second most serious medical condition with respect to global disease burden. It is clear that more effective pharmacotherapies are needed in treating depressive illn ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Akt Inhibitors to Treat Ewing's Sarcoma

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab of the Lombardi Cancer Center to create and preclinically evaluate novel inhibitors of the protein Akt. An Akt inhibitor would have tremendous value in improving the lives of patients with many types ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. Caspase Inhibitor for Neuroprotection

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuronal loss during normal development, after acute neuronal injury, and in chronic degenerative conditions such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Development of NET-Selective Piperidine-Based PET Ligand

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as depression. The economic burden of depression alone is immense. Of the $83.1 billion spent in 2000 on the treatment of depression and related expenses, $26.1 billion (31 percent) were direct medical cos ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands

    SBC: OCATA THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ability to culture human embryonic stem cells generated a great deal of excitement about their vast potential for treating a variety of human diseases such as diabetes, heart disease, neurological, retinal and skin disorders to name a few. Unlike adult stem cells, embryonic stem cells have indefinite growth potential and the potential to develop into any t ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Multi-Organizational Knowledge Based Approach Research

    SBC: 10 BLADE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase 1 STTR project will determine the feasibility of using web services, based on standard SOAP/XML (HL-7) protocols, to exchange Emergency Medical Services (EMS) field data with disparate hospital information systems. It will build upon a pre-hospital software package called iRevive, which consists of a network of wireless, handheld computers linked ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. HT-production of Abs using Interaction Trap in Yeast

    SBC: AFFOMIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Affomix would like to commercialize antibody chips to enable researchers to study the human proteome. Currently, researchers use gene chips as a surrogate means to estimate the concentration of the vast variety of pro teins in cells and tissues. But given the choice, most researchers would prefer to study the proteins directly because of the; i) poor correla ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. BROAD SPECTRUM BETA-LACTAMASE INHIBITORS

    SBC: ALAMX, LLC            Topic: N/A

    DESCRIPTION (Adapted from the application): Penicillin-resistant bacteria pose a serious threat to human welfare. This project will generate new products designed to defeat resistant microorganisms. The most prevalent cause of bacterial resistance involves the destruction of the antibiotic with the enzyme B-lactamase. There are more than 255 known B-lactamases, whi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Diffused Optical Tomography using Oxygen-sensitive Luminescent Contrast Agent for

    SBC: RADIATION MONITORING DEVICES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Molecule specific targeting and improving image contrast have been recognized as important research areas in cancer imaging. Goal of cancer diagnosis and prognosis research is to develop new imaging techniques to detect lesions with certainty in early stages so that they can be treated. Developing biomarkers, which will signal the presence and the type of lesio ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Production of High Specific Activity Lutetium-177

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A separation method will be tested and evaluated to determine the feasibility of providing no carrier added lutetium-177 (Lu-177) for use in radiotherapeutic applications. An indirect method will be used to produce Lu-177 (neutron capture followed by decay). Separation of the Lu-177 from the target material will enable us to provide carrier-free Lu-177 suita ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government